옵투스제약

131030KOSDAQ의약품 제조업

51.0 / 100

Reference Date: 2026-06-10

Financial Score30.5 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure4.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit metrics are weak. Plunged 32.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Optus Pharma specializes in developing and producing ophthalmic treatments for conditions such as dry eye and glaucoma, establishing a strong presence in the domestic market with products like Tierlin Pi eye drops. The company plans to expand its annual production capacity of single-use eye drops to 830 million units by 2026 with a new factory, while also growing its CMO/CDMO and global business segments to expand internationally.

Number of Employees

250people

Average Salary

54.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.82Industry Average 11.936.5Point

Lower than industry avg (good)

PBR

0.61Industry Average 0.895.5Point

Lower than industry avg (good)

ROE

7.36Industry Average 4.015.5Point

1.8x industry avg (good)

Debt Ratio

0.27Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲9.8% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.1% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 7.7% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Neutral
옵투스제약, 불성실공시법인 지정 유예
옵투스제약은 불성실공시법인 지정 유예를 받았으나, 이는 직접적인 부정적 영향보다는 관리 조치에 가깝다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 5,720Won52-week high 19,26052-week low 5,720

1-month return0.0Point

1m -32.55% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 1Negative 2

Negative불성실공시법인미지정 (지정유예)2026-05-29
Neutral분기보고서 (2026.03)2026-05-15
Negative불성실공시법인지정예고 (공시변경)2026-05-14